Morgan Stanley Entrada Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 346,756 shares of TRDA stock, worth $2.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

346,756

Previous 163,097 112.61%

Holding current value

$2.94 Million

Previous $1.1 Million 83.49%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$5.02 - $7.57 $921,968 - $1.39 Million	183,659 Added 112.61%	346,756 $2.01 Million
Q2 2025 Aug 15, 2025	BUY	$6.72 - $9.23 $601,009 - $825,494	89,436 Added 121.42%	163,097 $1.1 Million
Q1 2025 May 15, 2025	SELL	$9.04 - $18.31 $74,236 - $150,361	-8,212 Reduced 10.03%	73,661 $665,000
Q4 2024 Feb 14, 2025	SELL	$15.82 - $21.59 $180,237 - $245,974	-11,393 Reduced 12.22%	81,873 $1.42 Million
Q3 2024 May 14, 2025	BUY	$13.65 - $17.86 $603,534 - $789,679	44,215 Added 90.14%	93,266 $1.49 Million

Q3 2024 Nov 14, 2024	BUY	$13.65 - $17.86 $603,534 - $789,679	44,215 Added 90.14%	93,266 $1.49 Million
Q2 2024 May 14, 2025	SELL	$11.85 - $16.45 $388,940 - $539,921	-32,822 Reduced 40.09%	49,051 $698,000
Q2 2024 Oct 17, 2024	SELL	$11.85 - $16.45 $693,355 - $962,505	-58,511 Reduced 54.4%	49,051 $698,000
Q2 2024 Aug 14, 2024	SELL	$11.85 - $16.45 $693,355 - $962,505	-58,511 Reduced 54.4%	49,051 $698,000
Q1 2024 Oct 17, 2024	BUY	$11.58 - $17.0 $677,557 - $994,687	58,511 Added 119.29%	107,562 $1.52 Million
Q1 2024 Aug 16, 2024	BUY	$11.58 - $17.0 $674,627 - $990,386	58,258 Added 118.16%	107,562 $1.52 Million
Q1 2024 May 15, 2024	BUY	$11.58 - $17.0 $674,627 - $990,386	58,258 Added 118.16%	107,562 $1.52 Million
Q4 2023 Aug 16, 2024	BUY	$11.36 - $16.99 $2,874 - $4,298	253 Added 0.52%	49,304 $743,000
Q4 2023 Feb 13, 2024	BUY	$11.36 - $16.99 $322,146 - $481,802	28,358 Added 135.39%	49,304 $743,000
Q3 2023 Nov 15, 2023	SELL	$13.61 - $18.01 $121,904 - $161,315	-8,957 Reduced 29.95%	20,946 $330,000
Q2 2023 Aug 14, 2023	SELL	$11.02 - $18.01 $130,752 - $213,688	-11,865 Reduced 28.41%	29,903 $452,000
Q1 2023 May 15, 2023	BUY	$9.58 - $16.2 $161,729 - $273,488	16,882 Added 67.84%	41,768 $605,000
Q4 2022 Feb 14, 2023	BUY	$13.52 - $22.89 $194,093 - $328,608	14,356 Added 136.33%	24,886 $336,000
Q3 2022 Nov 14, 2022	SELL	$9.65 - $15.76 $102,820 - $167,922	-10,655 Reduced 50.3%	10,530 $166,000
Q2 2022 Oct 27, 2022	BUY	$5.49 - $12.94 $70,403 - $165,942	12,824 Added 153.38%	21,185 $258,000
Q2 2022 Aug 15, 2022	BUY	$5.49 - $12.94 $70,403 - $165,942	12,824 Added 153.38%	21,185 $258,000
Q1 2022 Oct 27, 2022	SELL	$7.99 - $16.93 $102,463 - $217,110	-12,824 Reduced 60.53%	8,361 $78,000
Q1 2022 May 13, 2022	BUY	$7.99 - $16.93 $33,550 - $71,089	4,199 Added 100.89%	8,361 $78,000
Q4 2021 Feb 14, 2022	BUY	$13.7 - $35.0 $57,019 - $145,670	4,162 New	4,162 $71,000

Others Institutions Holding TRDA

# of Institutions

117

Shares Held

27.9M

Call Options Held

13.7K

Put Options Held

14K

View Full List

About Entrada Therapeutics, Inc.

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $266M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

More about TRDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account